Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial is a phase 3, randomised interventional study registered as NCT06563388 by Roswell Park Cancer Institute, with a registry enrolment figure of 800 participants, started 2024-09-18 and due to reach its primary completion in 2032-09-18. Interventions recorded: Stereotactic Ablative Radiotherapy; Best Practice. Conditions listed: Oligometastasis; Lung Cancer; Colo-rectal Cancer; Prostate Cancer. Primary outcome: Overall Survival - Trial 1 and 2; Androgen DeprivationTherapy (ADT)-free survival - Trial 3. Colorectal eligibility wording from the registry: "* Trials 1-3: Histologically confirmed lung, prostate or colorectal malignancy with metastatic disease detected on imaging". Sites: United States. No results are recorded here; the registry entry is the source.